Please login to the form below
Pomalyst
This page shows the latest Pomalyst news and features for those working in and with pharma, biotech and healthcare.
In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa
The CHMP positive opinion is for Sarclisa (isatuximab) as a treatment for patients with relapsed and refractory multiple myeloma in combination with Bristol-Myers Squibb’s Pomalyst (pomalidomide) and dexamethasone – a
Latest news
-
BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma
Celgene’s Pomalyst/Innovid (pomalidomide) and dexamethasone in relapsed/refractory patients. ... BMS will draw some comfort from the fact that through its acquisition of Celgene it has claimed ownership of Revlimid and Pomalyst, plus other myeloma
-
FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma
The company is at the planning stages for a phase 3 trial of the drug – DREAMM3 – that will compare belantamab mafodotin to Celgene’s immuno-modulatory drug Pomalyst (pomalidomide) plus ... It is also set to evaluate the drug in a phase 1/2 trial
-
BMS’ Opdivo stalls in Q3, but overall figures still top expectations
and Pomalyst (pomalidomide) which grew 13% to $2.77bn and 29% to $664m, respectively.
-
GSK preps filings for BCMA-targeting multiple myeloma drug
It is already recruiting patients into a phase 1/2 trial (DREAMM-4) looking at the combination of the BCMA drug with Pomalyst, as well as six other studies looking at
-
Triplet approvals for myeloma boost Celgene in Q2
of triplet therapy which resulted in “increases in treatment duration and market share.” It was a similar story for Pomalyst/Imnovid (pomalidomide), up 22% to $619m, according to the company. ... transplant, with Pomalyst cleared with the same two
More from news
Approximately 3 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
BMS will become the fourth largest pharma firm by sales – behind Pfizer, Novartis and Roche – and the addition of new Celgene brands like blood cancer therapies Revlimid (lenalidomide) and Pomalyst (pomalidomide)
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- The Considered appoints Bam Zahraie as chief experience officer
- The impact of pharma congresses on HCPs – virtual and in person
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- A relentless commitment to neuroscience
- Alzheon says data backs potential of Alzheimer's candidate
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Regeneron’s application for Eylea in retinopathy of prematurity accepted for FDA priority review
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
